Flag of the European Union EU Clinical Trials Register Help

Clinical trials for VEGFR2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: VEGFR2. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-003209-10 Sponsor Protocol Number: ML18583 Start Date*: 2005-10-18
    Sponsor Name:Tampere University Hospital
    Full Title: VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment
    Medical condition: FIGO Stage III-IV serous epithelial ovarian carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001155-39 Sponsor Protocol Number: D8480C00016 Start Date*: 2012-03-09
    Sponsor Name:AstraZeneca AB
    Full Title: Phase I trial of AZD2171, an orally bioavailable antiangiogenic agent, in children and adolescents with refactory or recurrent solid tumours or acute myelogenous leukemia
    Medical condition: Refractory or recurrent solid tumours or acute myelogenous leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-005596-40 Sponsor Protocol Number: SFT-AX2014 Start Date*: 2014-03-14
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: Phase II Study of Axitinib in Advanced Solitary Fibrous Tumor
    Medical condition: Advanced solitary fibrous tumor
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019121-34 Sponsor Protocol Number: E-3810-I-01 Start Date*: 2011-03-28
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics, and Pharmacodynamics of the dual VEGFR-FGFR Tyrosine Kinase ...
    Medical condition: Dose escalation: solid tumors failing standard therapy. Dose-expansion: solid tumors A) with FGFR1 amplification and for breast cancer ? 1 prior endocrine therapy if ER+ or ? 1 chemotherapy otherwi...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-005169-78 Sponsor Protocol Number: P080301 Start Date*: 2009-02-23
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Traitement des récidives de glioblastomes par le SUTENT (SU11248) : essai de phase 2 avec étude translationnelle biologique et en imagerie
    Medical condition: Patients atteints de glioblastomes en récidive
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018336 Glioblastomes PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000699-40 Sponsor Protocol Number: BR55-102 Start Date*: 2012-07-26
    Sponsor Name:BRACCO IMAGING
    Full Title: A Study of BR55 in Contrast Enhanced Ultrasound Imaging in Patients with Ovarian and Breast Cancer.
    Medical condition: Patients with ovarian or breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014096-46 Sponsor Protocol Number: P090402 Start Date*: 2009-10-12
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Essai thérapeutique de phase IIa ouvert, multicentrique, évaluant l'intérêt du Pazopanib dans les dermatofibrosarcomes de Darier-ferrand (DFSP) inopérables ou localement avancés (intervention mutil...
    Medical condition: Dermatofibrosarcome protubérant (DFSP) ou sarcome de Darrier-Ferrand.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10057070 Dermatofibrosarcome protubérant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000975-21 Sponsor Protocol Number: RET-AFLI-2014-01 Start Date*: 2014-06-16
    Sponsor Name:Fundación Retinaplus +
    Full Title: A phase IV study to evaluate the effectiveness of aflibercept in naive patients with macular edema secondary to Central Retinal Vein Occlusion (CRVO) on an individualized Treat and Extend regimen. ...
    Medical condition: Macular edema secondary to central retinal vein occlusion.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000848-26 Sponsor Protocol Number: BMF-AFLI-2013-01 Start Date*: 2013-07-04
    Sponsor Name:Barcelona Macula Foundation
    Full Title: Phase IV study to evaluate the efficacy of aflibercept in subjects with neovascular age-related macular degeneration (wAMD), without optimal response to repeated monthly intravitreal injections of ...
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000300-10 Sponsor Protocol Number: IDI-AFLI-2013-01 Start Date*: 2014-04-23
    Sponsor Name:Fundació Instituto de Investigación Biomédica de Bellvitge (Fundació IDIBELL)
    Full Title: Phase IV study to evaluate the efficacy of aflibercept in naive patients with retinal angiomatous proliferation (RAP) lesions on an individualized ?Treat and Extend? (TAE) regimen. AFLIRAP Study.
    Medical condition: Retinal angiomatous proliferation lesions (RAP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018275-20 Sponsor Protocol Number: UMCNONCO201001 Start Date*: 2010-03-24
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion
    Medical condition: symptomatic malignant ascites or pleural effusion
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025538 Malignant ascites LLT
    12.1 10026673 Malignant pleural effusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002124-17 Sponsor Protocol Number: IMO-AFLI-2013-01 Start Date*: 2013-10-04
    Sponsor Name:Fundació de Recerca de L?Institut de Microcirurgia Ocular
    Full Title: Phase IV study to evaluate genetic variants of VEGF pathway as biomarkers of VEGF Trap-Eye treatment efficacy in subjects with neovascular age-related macular degeneration (wAMD).
    Medical condition: Wet age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-002700-21 Sponsor Protocol Number: OOI/Onkocytogenetika/2022/01 Start Date*: 2023-02-28
    Sponsor Name:National Institute of Oncology [...]
    1. National Institute of Oncology
    2. National Institute of Oncology
    Full Title: An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion
    Medical condition: Glioblastoma multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001207-68 Sponsor Protocol Number: KKSH140 Start Date*: 2018-11-20
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors
    Medical condition: Progressive well-differentiated metastatic pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    21.0 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002445-36 Sponsor Protocol Number: 0001 Start Date*: 2011-10-31
    Sponsor Name:Department of Clinical Oncology, Leiden University Medical Center
    Full Title: Neo-adjuvant dovitinib in patients with hepatocellular carcinoma prior to local treatment: a phase II study
    Medical condition: Hepatocellular carcinoma, not metastatic
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019830 Hepatocellular carcinoma resectable LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000087-16 Sponsor Protocol Number: CA182-026 Start Date*: 2009-03-16
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A randomized Discontinuation Study of Brivanib alaninate (BMS-582664) versus Placebo in Subjects with Advanced Tumors. Revised protocol 02 incorporating Amendment 02 & 03 & Administrative Lette...
    Medical condition: Subjects with Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024133-23 Sponsor Protocol Number: NO25530 Start Date*: 2011-10-31
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resista...
    Medical condition: Metastatic or unresectable papillary thyroid cancer positive for BRAFV600 mutation and resistant to radioactive iodine therapy
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10033701 Papillary thyroid cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004072-30 Sponsor Protocol Number: GETNE-1408 Start Date*: 2015-01-22
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos
    Full Title: A phase II trial to assess the activity and safety of TH-302 in combination with sunitinib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) pr...
    Medical condition: Patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumours (pNET).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-001180-11 Sponsor Protocol Number: ML20514 Start Date*: 2009-03-16
    Sponsor Name:Roche Pharma AG
    Full Title: An Open-label, single-arm, Phase II study to evaluate the efficacy and the feasibility of bevacizumab (Avastin®) based on a FOLFOXIRI regimen until progression in patients with previously untreated...
    Medical condition: previously untreated metastatic colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10010036 Colorectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002588-28 Sponsor Protocol Number: IEO S352/307 Start Date*: 2007-12-19
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: PHASE II STUDY OF METRONOMIC ORAL VINORELBINE IN ADVANCED BREAST CANCER
    Medical condition: Advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 05:30:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA